董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Edwin Moses | 男 | Chairman of the Board | 66 | 未披露 | 未持股 | 2021-03-30 |
| Martin Murphy | 男 | Director | 52 | 未披露 | 未持股 | 2021-03-30 |
| Michael F. Giordano | 男 | Director | 62 | 未披露 | 未持股 | 2021-03-30 |
| Roger Rooswinkel | -- | Director | 37 | 未披露 | 未持股 | 2021-03-30 |
| Iraj Ali | -- | Chief Executive Officer and Director | 45 | 未披露 | 未持股 | 2021-03-30 |
| Derek Paul Di Rocco | 男 | Director | 40 | 未披露 | 未持股 | 2021-03-30 |
| Carsten Boess | 男 | Director | 54 | 未披露 | 未持股 | 2021-03-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Lowdell | 男 | Founder | 58 | 未披露 | 未持股 | 2021-03-30 |
| Iraj Ali | -- | Chief Executive Officer and Director | 45 | 未披露 | 未持股 | 2021-03-30 |
| Robert Coutts | 男 | Chief Financial Officer | 37 | 未披露 | 未持股 | 2021-03-30 |
| Karl Peggs | -- | Chief Medical Officer and Founder | 54 | 未披露 | 未持股 | 2021-03-30 |
| Sergio Quezada | 男 | Chief Scientific Officer and Founder | 46 | 未披露 | 未持股 | 2021-03-30 |
| Charles Swanton | 男 | Founder | 49 | 未披露 | 未持股 | 2021-03-30 |
董事简历
中英对照 | 中文 | 英文- Edwin Moses
-
Edwin Moses自2018年12月起担任董事会主席兼成员。他曾担任Ablynx N.V.（或Ablynx，生物制药公司）的首席执行官（从2006年3月到2018年6月Ablynx&8217；s被赛诺菲收购）。Moses博士还于2004年至2018年担任Ablynx的董事会成员。Moses博士在谢菲尔德大学（University of Sheffield）获得化学学士学位和博士学位。
Edwin Moses has served as the Chairman and a member of our board of directors since December 2018. He was the Chief Executive Officer of Ablynx N.V., or Ablynx, a biopharmaceutical company, a position he held from March 2006 until Ablynx’s acquisition by Sanofi in June 2018. Dr. Moses also served on the board of directors of Ablynx from 2004 until 2018. Dr. Moses received his B.S. and Ph.D. in Chemistry from the University of Sheffield. - Edwin Moses自2018年12月起担任董事会主席兼成员。他曾担任Ablynx N.V.（或Ablynx，生物制药公司）的首席执行官（从2006年3月到2018年6月Ablynx&8217；s被赛诺菲收购）。Moses博士还于2004年至2018年担任Ablynx的董事会成员。Moses博士在谢菲尔德大学（University of Sheffield）获得化学学士学位和博士学位。
- Edwin Moses has served as the Chairman and a member of our board of directors since December 2018. He was the Chief Executive Officer of Ablynx N.V., or Ablynx, a biopharmaceutical company, a position he held from March 2006 until Ablynx’s acquisition by Sanofi in June 2018. Dr. Moses also served on the board of directors of Ablynx from 2004 until 2018. Dr. Moses received his B.S. and Ph.D. in Chemistry from the University of Sheffield.
- Martin Murphy
-
Martin Murphy自2018年1月起担任我们的董事会成员，并将在本招股说明书所包含的注册声明生效之前立即辞职。Murphy博士自2016年12月起担任Syncona Investment Management Limited（Syncona的一部分）的首席执行官。Murphy博士是Syncona Partners LLP的创始人，并于2012年5月至2016年12月担任其首席执行官。自2014年9月以来，他一直担任Autolus Therapeutics plc的董事会成员。Murphy博士在剑桥大学（University of Cambridge）获得生物化学博士学位，在牛津大学（University of Oxford）获得生物化学硕士学位。
Martin Murphy,served as Chair of Syncona Investment Management Limited, part of the global life science company Syncona Ltd., from January 2023 until November 2023, as the chief executive officer of Syncona Investment Management Limited from December 2016 until December 2022, and founded Syncona Partners LLP and served as its chief executive officer from May 2012 to December 2016. Prior to that, he was a partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcare investments, from 2003 to 2012. During his time at MVM, Dr. Murphy was a member of the management and investment committees and led MVM's European operations. Before MVM, Dr. Murphy worked at 3i Group plc and McKinsey & Company. Since January 2025, Dr. Murphy has served as a non-executive director of Synairgen plc, a specialist respiratory biotech company listed on the London Stock Exchange. He has a Ph.D. in Biochemistry from the University of Cambridge. - Martin Murphy自2018年1月起担任我们的董事会成员，并将在本招股说明书所包含的注册声明生效之前立即辞职。Murphy博士自2016年12月起担任Syncona Investment Management Limited（Syncona的一部分）的首席执行官。Murphy博士是Syncona Partners LLP的创始人，并于2012年5月至2016年12月担任其首席执行官。自2014年9月以来，他一直担任Autolus Therapeutics plc的董事会成员。Murphy博士在剑桥大学（University of Cambridge）获得生物化学博士学位，在牛津大学（University of Oxford）获得生物化学硕士学位。
- Martin Murphy,served as Chair of Syncona Investment Management Limited, part of the global life science company Syncona Ltd., from January 2023 until November 2023, as the chief executive officer of Syncona Investment Management Limited from December 2016 until December 2022, and founded Syncona Partners LLP and served as its chief executive officer from May 2012 to December 2016. Prior to that, he was a partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcare investments, from 2003 to 2012. During his time at MVM, Dr. Murphy was a member of the management and investment committees and led MVM's European operations. Before MVM, Dr. Murphy worked at 3i Group plc and McKinsey & Company. Since January 2025, Dr. Murphy has served as a non-executive director of Synairgen plc, a specialist respiratory biotech company listed on the London Stock Exchange. He has a Ph.D. in Biochemistry from the University of Cambridge.
- Michael F. Giordano
-
MichaelF.Giordano自2018年9月以来一直担任我们的董事会成员。佐丹奴博士曾于2017年12月至2018年8月担任生物制药公司Epizyme，Inc.（Epizyme）的临床顾问和临时首席医疗官。Giordano博士于1999年至2017年在制药公司百时美施贵宝公司工作，最近于2012年2月至2017年2月担任高级副总裁兼肿瘤和免疫肿瘤学开发主管。佐丹奴博士还自2018年3月起担任Epizyme的董事会成员，并自2018年2月起担任RAPTTherapeutics，Inc.的董事会成员。他获得了医学博士学位，在纽约长老会-威尔·康奈尔医学中心完成了住院医师和奖学金培训，并在约翰霍普金斯大学获得自然科学学士学位。
Michael F. Giordano has served on our board of directors since September 2018. Dr. Giordano has served as a Clinical Advisor and Interim Chief Medical Officer to Epizyme, Inc., or Epizyme, a biopharmaceutical company, from December 2017 to August 2018. From 1999 to 2017 Dr. Giordano worked at Bristol-Myers Squibb Company, a pharmaceutical company, most recently serving as Senior Vice President and Head of Development, Oncology and Immuno-Oncology from February 2012 to February 2017. Dr. Giordano has also served on the board of directors of Epizyme since March 2018 and on the board of directors of RAPT Therapeutics, Inc. since February 2018. He earned his M.D. and completed his residency and fellowship training at New York Presbyterian-Weill Cornell Medical Center, and received his B.A. in Natural Sciences from The Johns Hopkins University. - MichaelF.Giordano自2018年9月以来一直担任我们的董事会成员。佐丹奴博士曾于2017年12月至2018年8月担任生物制药公司Epizyme，Inc.（Epizyme）的临床顾问和临时首席医疗官。Giordano博士于1999年至2017年在制药公司百时美施贵宝公司工作，最近于2012年2月至2017年2月担任高级副总裁兼肿瘤和免疫肿瘤学开发主管。佐丹奴博士还自2018年3月起担任Epizyme的董事会成员，并自2018年2月起担任RAPTTherapeutics，Inc.的董事会成员。他获得了医学博士学位，在纽约长老会-威尔·康奈尔医学中心完成了住院医师和奖学金培训，并在约翰霍普金斯大学获得自然科学学士学位。
- Michael F. Giordano has served on our board of directors since September 2018. Dr. Giordano has served as a Clinical Advisor and Interim Chief Medical Officer to Epizyme, Inc., or Epizyme, a biopharmaceutical company, from December 2017 to August 2018. From 1999 to 2017 Dr. Giordano worked at Bristol-Myers Squibb Company, a pharmaceutical company, most recently serving as Senior Vice President and Head of Development, Oncology and Immuno-Oncology from February 2012 to February 2017. Dr. Giordano has also served on the board of directors of Epizyme since March 2018 and on the board of directors of RAPT Therapeutics, Inc. since February 2018. He earned his M.D. and completed his residency and fellowship training at New York Presbyterian-Weill Cornell Medical Center, and received his B.A. in Natural Sciences from The Johns Hopkins University.
- Roger Rooswinkel
-
Roger Rooswinkel自2019年9月以来一直担任我们的董事会成员。Rooswinkel博士从2013年4月开始一直担任Forbion IV Management B.V.的合伙人，这是一家风险投资基金，并通过其关联公司Forbion Capital Fund IV Cooperatief U.A.担任该公司的大股东。Rooswinkel博士拥有荷兰阿姆斯特丹大学（University of Amsterdam，Netherlands）肿瘤学博士学位，理学硕士学位。荷兰阿姆斯特丹自由大学肿瘤学学士学位和荷兰自由大学医学自然科学学士学位。
Roger Rooswinkel has served as a member of our board of directors since September 2019. Dr. Rooswinkel has been a Partner at Forbion IV Management B.V., a venture capital fund and through its affiliate, Forbion Capital Fund IV Cooperatief U.A., a major shareholder of our company, since April 2013. Dr. Rooswinkel holds a Ph.D. in Oncology from the University of Amsterdam, Netherlands, a M.Sc. in Oncology from the Vrije Universiteit Amsterdam, Netherlands, and a B.S. in Medical Natural Sciences from the Free University, Netherlands. - Roger Rooswinkel自2019年9月以来一直担任我们的董事会成员。Rooswinkel博士从2013年4月开始一直担任Forbion IV Management B.V.的合伙人，这是一家风险投资基金，并通过其关联公司Forbion Capital Fund IV Cooperatief U.A.担任该公司的大股东。Rooswinkel博士拥有荷兰阿姆斯特丹大学（University of Amsterdam，Netherlands）肿瘤学博士学位，理学硕士学位。荷兰阿姆斯特丹自由大学肿瘤学学士学位和荷兰自由大学医学自然科学学士学位。
- Roger Rooswinkel has served as a member of our board of directors since September 2019. Dr. Rooswinkel has been a Partner at Forbion IV Management B.V., a venture capital fund and through its affiliate, Forbion Capital Fund IV Cooperatief U.A., a major shareholder of our company, since April 2013. Dr. Rooswinkel holds a Ph.D. in Oncology from the University of Amsterdam, Netherlands, a M.Sc. in Oncology from the Vrije Universiteit Amsterdam, Netherlands, and a B.S. in Medical Natural Sciences from the Free University, Netherlands.
- Iraj Ali
-
Iraj Ali自2018年1月起担任首席执行官，自2016年3月起担任董事会成员。此前，阿里博士于2016年12月至2018年12月担任Syncona Ltd.或Syncona的管理合伙人，Syncona是一家领先的梦百合投资公司，专注于创立，建立和资助全球生命科学领导者，也是我们公司的主要股东。阿里博士也曾于2012年9月至2018年12月担任Syncona的投资合伙人。Ali博士在剑桥大学（Cambridge University）获得生物化学博士学位，在雷丁大学（University of Reading）获得生物化学学士学位。
Iraj Ali has served as our Chief Executive Officer since January 2018 and a member of our board of directors since March 2016. Previously, Dr. Ali served as a Managing Partner of Syncona Ltd., or Syncona, a leading healthcare investment company focused on founding, building and funding global leaders in life sciences and a major shareholder of our company, from December 2016 to December 2018. Dr. Ali was also an Investment Partner at Syncona from September 2012 to December 2018. Dr. Ali has a Ph.D. in Biochemistry from Cambridge University and a B.S. in Biochemistry from the University of Reading. - Iraj Ali自2018年1月起担任首席执行官，自2016年3月起担任董事会成员。此前，阿里博士于2016年12月至2018年12月担任Syncona Ltd.或Syncona的管理合伙人，Syncona是一家领先的梦百合投资公司，专注于创立，建立和资助全球生命科学领导者，也是我们公司的主要股东。阿里博士也曾于2012年9月至2018年12月担任Syncona的投资合伙人。Ali博士在剑桥大学（Cambridge University）获得生物化学博士学位，在雷丁大学（University of Reading）获得生物化学学士学位。
- Iraj Ali has served as our Chief Executive Officer since January 2018 and a member of our board of directors since March 2016. Previously, Dr. Ali served as a Managing Partner of Syncona Ltd., or Syncona, a leading healthcare investment company focused on founding, building and funding global leaders in life sciences and a major shareholder of our company, from December 2016 to December 2018. Dr. Ali was also an Investment Partner at Syncona from September 2012 to December 2018. Dr. Ali has a Ph.D. in Biochemistry from Cambridge University and a B.S. in Biochemistry from the University of Reading.
- Derek Paul Di Rocco
-
Derek Paul Di Rocco，Di Rocco 博士自2020年起担任RA Capital Management,L.P.（RA Capital，一家致力于医疗保健及生命科学领域循证投资的多阶段投资管理公司）的合伙人，彼自2017年至2020年曾担任其负责人，并在2013年加入RA Capital 。Di Rocco 博士作为RA Capital 的代表，自2019年9月起担任Achilles Therapeutics plc（纳斯达克：ACHL）的非执行董事，并自2020年12月、2020年8月、2020年3月及2018年3月起分别担任Werewolf Therapeutics,Inc.（纳斯达克：HOWL）、Connect Biopharma Holdings Limited（纳斯达克：CNTB）、iTeos Therapeutics,Inc.（纳斯达克：ITOS）及89bio,Inc.（纳斯达克：ETNB）的非执行董事。于2020年3月获委任为北海康成制药有限公司董事，并于2021年6月21日调任非执行董事。Di Rocco 博士于2002年5月在圣十字学院获得生物学学士学位，并于2009年8月在华盛顿大学获得药理学博士学位。于2021年06月21日获委任为北海康成制药有限公司提名及企业管治委员会委员。
Derek Paul Di Rocco,has served as a member of Connect Biopharma Holdings Limited board of directors since August 2020. Dr. DiRocco has been a principal at RA Capital Management since December 2017 and was previously an analyst from June 2015 to December 2017 and an associate from July 2013 to June 2015. Dr. DiRocco has served on the boards of directors of iTeos Therapeutics,Inc.,CANbridge Pharmaceuticals Inc.,Achilles Therapeutics Ltd. and 89bio,Inc. since March 2020,February 2020,September 2019 and May 2018,respectively. Dr. DiRocco holds a B.A. in Biology from College of the Holy Cross and a Ph.D. in Pharmacology from the University of Washington. - Derek Paul Di Rocco，Di Rocco 博士自2020年起担任RA Capital Management,L.P.（RA Capital，一家致力于医疗保健及生命科学领域循证投资的多阶段投资管理公司）的合伙人，彼自2017年至2020年曾担任其负责人，并在2013年加入RA Capital 。Di Rocco 博士作为RA Capital 的代表，自2019年9月起担任Achilles Therapeutics plc（纳斯达克：ACHL）的非执行董事，并自2020年12月、2020年8月、2020年3月及2018年3月起分别担任Werewolf Therapeutics,Inc.（纳斯达克：HOWL）、Connect Biopharma Holdings Limited（纳斯达克：CNTB）、iTeos Therapeutics,Inc.（纳斯达克：ITOS）及89bio,Inc.（纳斯达克：ETNB）的非执行董事。于2020年3月获委任为北海康成制药有限公司董事，并于2021年6月21日调任非执行董事。Di Rocco 博士于2002年5月在圣十字学院获得生物学学士学位，并于2009年8月在华盛顿大学获得药理学博士学位。于2021年06月21日获委任为北海康成制药有限公司提名及企业管治委员会委员。
- Derek Paul Di Rocco,has served as a member of Connect Biopharma Holdings Limited board of directors since August 2020. Dr. DiRocco has been a principal at RA Capital Management since December 2017 and was previously an analyst from June 2015 to December 2017 and an associate from July 2013 to June 2015. Dr. DiRocco has served on the boards of directors of iTeos Therapeutics,Inc.,CANbridge Pharmaceuticals Inc.,Achilles Therapeutics Ltd. and 89bio,Inc. since March 2020,February 2020,September 2019 and May 2018,respectively. Dr. DiRocco holds a B.A. in Biology from College of the Holy Cross and a Ph.D. in Pharmacology from the University of Washington.
- Carsten Boess
-
Carsten Boess 自 2016 年 1 月起担任 Rocket Pharmaceuticals, Inc. 的董事之一。他目前是私营生物技术公司 Kiniksa Pharmaceuticals 的企业事务执行副总裁。他曾在 2011 年担任 Synageva Biopharma Corporation 的高级副总裁兼首席财务官，直到Synageva Biopharma Corporation 于 2015 年被 Alexion Pharmaceuticals 收购。在加入 Synageva 之前，Boess 先生曾担任多个职务，对 Insulet Corporation 的责任越来越大，包括首席财务官2006 年至 2009 年担任财务官，2009 年至 2011 年担任国际运营副总裁。在此之前，Boess 先生于 2005 年至 2006 年担任雪兰诺公司的财务执行副总裁。此外，他还是日内瓦的成员在雪兰诺期间，总部位于全球执行财务管理团队。 Boess 先生还曾担任 Alexion Pharmaceuticals 的首席财务官，以及北美 Novozymes 和法国、瑞士和中国的 Novo Nordisk 的财务主管。 Boess 先生获得丹麦欧登塞大学会计与金融专业的经济学和金融学学士和硕士学位。
Carsten Boess has served as one of Rocket Pharmaceuticals, Inc. directors since January 2016. He is currently the Executive Vice President of Corporate Affairs at Kiniksa Pharmaceuticals, a privately held biotechnology company. He previously served as Senior Vice President and Chief Financial Officer at Synageva Biopharma Corporation from 2011 until the company's acquisition by Alexion Pharmaceuticals in 2015. Prior to his role at Synageva, Mr. Boess served in multiple roles with increasing responsibility for Insulet Corporation, including Chief Financial Officer from 2006 to 2009 and Vice President of International Operations from 2009 to 2011. Prior to that, Mr. Boess served as Executive Vice President of Finance for Serono Inc. from 2005 to 2006. In addition, he was a member of the Geneva based World Wide Executive Finance Management Team while at Serono. Mr. Boess was also Chief Financial Officer at Alexion Pharmaceuticals and was a finance executive at Novozymes of North America and Novo Nordisk in France, Switzerland and China. Mr. Boess received a Bachelor's degree and Master's degree in Economics and Finance, specializing in Accounting and Finance from the University of Odense, Denmark. - Carsten Boess 自 2016 年 1 月起担任 Rocket Pharmaceuticals, Inc. 的董事之一。他目前是私营生物技术公司 Kiniksa Pharmaceuticals 的企业事务执行副总裁。他曾在 2011 年担任 Synageva Biopharma Corporation 的高级副总裁兼首席财务官，直到Synageva Biopharma Corporation 于 2015 年被 Alexion Pharmaceuticals 收购。在加入 Synageva 之前，Boess 先生曾担任多个职务，对 Insulet Corporation 的责任越来越大，包括首席财务官2006 年至 2009 年担任财务官，2009 年至 2011 年担任国际运营副总裁。在此之前，Boess 先生于 2005 年至 2006 年担任雪兰诺公司的财务执行副总裁。此外，他还是日内瓦的成员在雪兰诺期间，总部位于全球执行财务管理团队。 Boess 先生还曾担任 Alexion Pharmaceuticals 的首席财务官，以及北美 Novozymes 和法国、瑞士和中国的 Novo Nordisk 的财务主管。 Boess 先生获得丹麦欧登塞大学会计与金融专业的经济学和金融学学士和硕士学位。
- Carsten Boess has served as one of Rocket Pharmaceuticals, Inc. directors since January 2016. He is currently the Executive Vice President of Corporate Affairs at Kiniksa Pharmaceuticals, a privately held biotechnology company. He previously served as Senior Vice President and Chief Financial Officer at Synageva Biopharma Corporation from 2011 until the company's acquisition by Alexion Pharmaceuticals in 2015. Prior to his role at Synageva, Mr. Boess served in multiple roles with increasing responsibility for Insulet Corporation, including Chief Financial Officer from 2006 to 2009 and Vice President of International Operations from 2009 to 2011. Prior to that, Mr. Boess served as Executive Vice President of Finance for Serono Inc. from 2005 to 2006. In addition, he was a member of the Geneva based World Wide Executive Finance Management Team while at Serono. Mr. Boess was also Chief Financial Officer at Alexion Pharmaceuticals and was a finance executive at Novozymes of North America and Novo Nordisk in France, Switzerland and China. Mr. Boess received a Bachelor's degree and Master's degree in Economics and Finance, specializing in Accounting and Finance from the University of Odense, Denmark.
高管简历
中英对照 | 中文 | 英文- Mark Lowdell
Mark Lowdell是我们的创始人之一。Lowdell博士自2015年10月起担任临床阶段免疫肿瘤学公司Inmune Bio，Inc.的首席科学官。Lowdell博士还从1994年1月开始担任伦敦大学学院（University College London）的细胞与组织疗法教授，并从2009年2月开始担任皇家自由伦敦国民保健服务基金会信托基金（Royal Free London NHS Foundation Trust）的细胞疗法总监。Lowdell博士是Inmune Bio Inc.的联合创始人，他于2018年4月在纳斯达克IPO，并于2015年9月至2018年7月担任董事会成员。Lowdell博士于1992年在伦敦大学伦敦医院医学院（London Hospital Medical College，University of London）获得临床免疫学博士学位，并在皇家病理学家学院（Royal College of Pathologists）完成研究金培训。他是合格的免疫病理学家，以及细胞和基因治疗药物认证的欧盟合格人士。
Mark Lowdell is one of our founders. Dr. Lowdell has served as the Chief Scientific Officer of INmune Bio, Inc., a clinical stage immuno-oncology company, since October 2015. Dr. Lowdell has also been a Professor of Cell and Tissue Therapy at University College London since January 1994 and Director of Cellular Therapy at the Royal Free London NHS Foundation Trust since February 2009. Dr. Lowdell is a co-founder of INmune Bio Inc which he took through IPO on Nasdaq in April 2018 and served on the board of directors from September 2015 to July 2018. Dr. Lowdell received his Ph.D. in Clinical Immunology from London Hospital Medical College, University of London in 1992 and completed his fellowship training at the Royal College of Pathologists. He is a qualified immunopathologist and an EU Qualified Person for the certification of cell and gene therapy medicines.- Mark Lowdell是我们的创始人之一。Lowdell博士自2015年10月起担任临床阶段免疫肿瘤学公司Inmune Bio，Inc.的首席科学官。Lowdell博士还从1994年1月开始担任伦敦大学学院（University College London）的细胞与组织疗法教授，并从2009年2月开始担任皇家自由伦敦国民保健服务基金会信托基金（Royal Free London NHS Foundation Trust）的细胞疗法总监。Lowdell博士是Inmune Bio Inc.的联合创始人，他于2018年4月在纳斯达克IPO，并于2015年9月至2018年7月担任董事会成员。Lowdell博士于1992年在伦敦大学伦敦医院医学院（London Hospital Medical College，University of London）获得临床免疫学博士学位，并在皇家病理学家学院（Royal College of Pathologists）完成研究金培训。他是合格的免疫病理学家，以及细胞和基因治疗药物认证的欧盟合格人士。
- Mark Lowdell is one of our founders. Dr. Lowdell has served as the Chief Scientific Officer of INmune Bio, Inc., a clinical stage immuno-oncology company, since October 2015. Dr. Lowdell has also been a Professor of Cell and Tissue Therapy at University College London since January 1994 and Director of Cellular Therapy at the Royal Free London NHS Foundation Trust since February 2009. Dr. Lowdell is a co-founder of INmune Bio Inc which he took through IPO on Nasdaq in April 2018 and served on the board of directors from September 2015 to July 2018. Dr. Lowdell received his Ph.D. in Clinical Immunology from London Hospital Medical College, University of London in 1992 and completed his fellowship training at the Royal College of Pathologists. He is a qualified immunopathologist and an EU Qualified Person for the certification of cell and gene therapy medicines.
- Iraj Ali
Iraj Ali自2018年1月起担任首席执行官，自2016年3月起担任董事会成员。此前，阿里博士于2016年12月至2018年12月担任Syncona Ltd.或Syncona的管理合伙人，Syncona是一家领先的梦百合投资公司，专注于创立，建立和资助全球生命科学领导者，也是我们公司的主要股东。阿里博士也曾于2012年9月至2018年12月担任Syncona的投资合伙人。Ali博士在剑桥大学（Cambridge University）获得生物化学博士学位，在雷丁大学（University of Reading）获得生物化学学士学位。
Iraj Ali has served as our Chief Executive Officer since January 2018 and a member of our board of directors since March 2016. Previously, Dr. Ali served as a Managing Partner of Syncona Ltd., or Syncona, a leading healthcare investment company focused on founding, building and funding global leaders in life sciences and a major shareholder of our company, from December 2016 to December 2018. Dr. Ali was also an Investment Partner at Syncona from September 2012 to December 2018. Dr. Ali has a Ph.D. in Biochemistry from Cambridge University and a B.S. in Biochemistry from the University of Reading.- Iraj Ali自2018年1月起担任首席执行官，自2016年3月起担任董事会成员。此前，阿里博士于2016年12月至2018年12月担任Syncona Ltd.或Syncona的管理合伙人，Syncona是一家领先的梦百合投资公司，专注于创立，建立和资助全球生命科学领导者，也是我们公司的主要股东。阿里博士也曾于2012年9月至2018年12月担任Syncona的投资合伙人。Ali博士在剑桥大学（Cambridge University）获得生物化学博士学位，在雷丁大学（University of Reading）获得生物化学学士学位。
- Iraj Ali has served as our Chief Executive Officer since January 2018 and a member of our board of directors since March 2016. Previously, Dr. Ali served as a Managing Partner of Syncona Ltd., or Syncona, a leading healthcare investment company focused on founding, building and funding global leaders in life sciences and a major shareholder of our company, from December 2016 to December 2018. Dr. Ali was also an Investment Partner at Syncona from September 2012 to December 2018. Dr. Ali has a Ph.D. in Biochemistry from Cambridge University and a B.S. in Biochemistry from the University of Reading.
- Robert Coutts
Robert Coutts自2020年11月起担任我们的首席财务官。此前，Coutts先生于2017年11月至2020年11月担任我们的财务总监，并于2015年6月至2017年11月担任Syncona的子公司财务总监。Coutts先生拥有硕士学位。在城市大学卡斯商学院获得管理学学士学位，在牛津大学新学院获得政治，哲学和经济学学士学位，是一名合格的特许会计师。
Robert Coutts has served as our Chief Financial Officer since November 2020. Previously, Mr. Coutts served as our Finance Director, from November 2017 to November 2020 and as Subsidiary Financial Controller at Syncona from June 2015 to November 2017. Mr. Coutts has a M.Sc. in Management from the Cass Business School, City University and a B.A. in Politics, Philosophy and Economics from New College, Oxford University and is a qualified chartered accountant.- Robert Coutts自2020年11月起担任我们的首席财务官。此前，Coutts先生于2017年11月至2020年11月担任我们的财务总监，并于2015年6月至2017年11月担任Syncona的子公司财务总监。Coutts先生拥有硕士学位。在城市大学卡斯商学院获得管理学学士学位，在牛津大学新学院获得政治，哲学和经济学学士学位，是一名合格的特许会计师。
- Robert Coutts has served as our Chief Financial Officer since November 2020. Previously, Mr. Coutts served as our Finance Director, from November 2017 to November 2020 and as Subsidiary Financial Controller at Syncona from June 2015 to November 2017. Mr. Coutts has a M.Sc. in Management from the Cass Business School, City University and a B.A. in Politics, Philosophy and Economics from New College, Oxford University and is a qualified chartered accountant.
- Karl Peggs
Karl Peggs是我们的创始人之一，自2021年1月以来一直担任我们的首席医疗官。从2016年5月至2020年12月，Peggs博士担任我们的董事会成员。Peggs博士在剑桥大学（Cambridge University）获得硕士学位，工商管理硕士学位，工商管理硕士学位。毕业于牛津大学医学院，是皇家医学院的成员和皇家病理学家学院的研究员。
Karl Peggs is one of our founders and has served as our Chief Medical Officer since January 2021. From May 2016 to December 2020 Dr. Peggs served on our board of directors. Dr. Peggs received a M.A. from Cambridge University, a M.B., B.Ch. from Oxford University Medical School and is a Member of the Royal College of Medicine and Fellow of the Royal College of Pathologists.- Karl Peggs是我们的创始人之一，自2021年1月以来一直担任我们的首席医疗官。从2016年5月至2020年12月，Peggs博士担任我们的董事会成员。Peggs博士在剑桥大学（Cambridge University）获得硕士学位，工商管理硕士学位，工商管理硕士学位。毕业于牛津大学医学院，是皇家医学院的成员和皇家病理学家学院的研究员。
- Karl Peggs is one of our founders and has served as our Chief Medical Officer since January 2021. From May 2016 to December 2020 Dr. Peggs served on our board of directors. Dr. Peggs received a M.A. from Cambridge University, a M.B., B.Ch. from Oxford University Medical School and is a Member of the Royal College of Medicine and Fellow of the Royal College of Pathologists.
- Sergio Quezada
Sergio Quezada是我们的创始人之一，自2020年4月以来一直担任我们的首席科学官。他也一直担任University College London Cancer Institute的癌症免疫学和免疫疗法教授（2011年1月以来），以及癌症研究英国（Cruk）的高级癌症研究员（2011年1月以来）。此前，Quezada博士曾为Tusk Therapeutics Ltd.（一家专注于开发新型免疫肿瘤学产品的公司）共同领导开发用于调节T细胞耗竭的新型抗体。Quezada博士拥有达特茅斯医学院（Dartmouth Medical School）的博士学位和智利天主教教皇大学（Pontificia Universidad Cat&243；Lica de Chile）的生物化学与分子生物学学士学位。从2004年到2010年，Quezada博士在Memorial Sloan-Kettering Cancer Center完成博士后培训。
Sergio Quezada is one of our founders and has served as our Chief Scientific Officer since April 2020. He has also been a Professor of Cancer Immunology and Immunotherapy at University College London Cancer Institute since January 2011 as well as a Cancer Research UK, or CRUK, senior cancer research fellow since January 2011. Previously, Dr. Quezada co-led the development of novel antibody for the depletion of regulatory T cells for TUSK Therapeutics Ltd., a company focused on developing novel immuno-oncology products. Dr. Quezada holds a Ph.D. from Dartmouth Medical School and a B.S. in Biochemistry and Molecular Biology from the Pontificia Universidad Católica de Chile. From 2004 to 2010 Dr. Quezada completed his post-doctoral training at Memorial Sloan-Kettering Cancer Center.- Sergio Quezada是我们的创始人之一，自2020年4月以来一直担任我们的首席科学官。他也一直担任University College London Cancer Institute的癌症免疫学和免疫疗法教授（2011年1月以来），以及癌症研究英国（Cruk）的高级癌症研究员（2011年1月以来）。此前，Quezada博士曾为Tusk Therapeutics Ltd.（一家专注于开发新型免疫肿瘤学产品的公司）共同领导开发用于调节T细胞耗竭的新型抗体。Quezada博士拥有达特茅斯医学院（Dartmouth Medical School）的博士学位和智利天主教教皇大学（Pontificia Universidad Cat&243；Lica de Chile）的生物化学与分子生物学学士学位。从2004年到2010年，Quezada博士在Memorial Sloan-Kettering Cancer Center完成博士后培训。
- Sergio Quezada is one of our founders and has served as our Chief Scientific Officer since April 2020. He has also been a Professor of Cancer Immunology and Immunotherapy at University College London Cancer Institute since January 2011 as well as a Cancer Research UK, or CRUK, senior cancer research fellow since January 2011. Previously, Dr. Quezada co-led the development of novel antibody for the depletion of regulatory T cells for TUSK Therapeutics Ltd., a company focused on developing novel immuno-oncology products. Dr. Quezada holds a Ph.D. from Dartmouth Medical School and a B.S. in Biochemistry and Molecular Biology from the Pontificia Universidad Católica de Chile. From 2004 to 2010 Dr. Quezada completed his post-doctoral training at Memorial Sloan-Kettering Cancer Center.
- Charles Swanton
Charles Swanton是我们的创始人之一。Swanton博士自2016年起担任皇家学会Napier癌症教授，自2011年起担任UCL Hospitals胸肿瘤科顾问。Swanton博士自2017年起还担任CRUK癌症进化和基因组不稳定实验室的首席临床医生，自2008年起担任CRUK肺癌卓越中心的Francis Crick研究所的组长。以及是UK Cancer Evolution Program Tracerx的首席研究员，他自2013年以来一直担任该职位。Swanton博士拥有UCL医学院细胞生物学和免疫学的M.B.，B.S.和一级荣誉学位，以及帝国癌症研究基金的博士学位。他是皇家医学院院士-2011年医学科学院院士-2015年皇家学会院士-2018年和美国癌症研究协会院士-2020年。
Charles Swanton is one of our founders. Dr. Swanton has also been a Royal Society Napier Professor of Cancer since 2016 and consultant thoracic oncologist at UCL Hospitals since 2011. Dr. Swanton has also served as Chief Clinician at CRUK since 2017 group Leader of the Cancer Evolution and Genome Instability laboratory at CRUK and the Francis Crick Institute since 2008 co-director of the CRUK Lung Cancer Centre of Excellence since 2008 and is chief investigator of the UK cancer evolution program TRACERx, a position he has held since 2013. Dr. Swanton holds an M.B., B.S. and first class honors degree in Cell Biology and Immunology from UCL medical schools and a Ph.D. from the Imperial Cancer Research Fund. He is a Fellow of the Royal College of Physicians -2011 Fellow of the Academy of Medical Sciences -2015 Fellow of the Royal Society -2018 and a Fellow of the American Association for Cancer Research -2020.- Charles Swanton是我们的创始人之一。Swanton博士自2016年起担任皇家学会Napier癌症教授，自2011年起担任UCL Hospitals胸肿瘤科顾问。Swanton博士自2017年起还担任CRUK癌症进化和基因组不稳定实验室的首席临床医生，自2008年起担任CRUK肺癌卓越中心的Francis Crick研究所的组长。以及是UK Cancer Evolution Program Tracerx的首席研究员，他自2013年以来一直担任该职位。Swanton博士拥有UCL医学院细胞生物学和免疫学的M.B.，B.S.和一级荣誉学位，以及帝国癌症研究基金的博士学位。他是皇家医学院院士-2011年医学科学院院士-2015年皇家学会院士-2018年和美国癌症研究协会院士-2020年。
- Charles Swanton is one of our founders. Dr. Swanton has also been a Royal Society Napier Professor of Cancer since 2016 and consultant thoracic oncologist at UCL Hospitals since 2011. Dr. Swanton has also served as Chief Clinician at CRUK since 2017 group Leader of the Cancer Evolution and Genome Instability laboratory at CRUK and the Francis Crick Institute since 2008 co-director of the CRUK Lung Cancer Centre of Excellence since 2008 and is chief investigator of the UK cancer evolution program TRACERx, a position he has held since 2013. Dr. Swanton holds an M.B., B.S. and first class honors degree in Cell Biology and Immunology from UCL medical schools and a Ph.D. from the Imperial Cancer Research Fund. He is a Fellow of the Royal College of Physicians -2011 Fellow of the Academy of Medical Sciences -2015 Fellow of the Royal Society -2018 and a Fellow of the American Association for Cancer Research -2020.